Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 9/20 | 0.33 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22124843 | 1.00 | P2RX3 (0.35) | P2RX3PTK6TTKMAPKAPK5FLT3 | |
| SCHEMBL22124784 | 0.96 | P2RX3 (0.35) | P2RX3PTK6TTKMAPKAPK5FLT3 | |
| SCHEMBL22124577 | 0.94 | MAPKAPK5 (0.34) | P2RX3PTK6TTKMAPKAPK5CDK2 | |
| SCHEMBL22122966 | 0.94 | P2RX3 (0.36) | P2RX3PTK6TTKMAPKAPK5FLT3 | |
| SCHEMBL22124706 | 0.93 | PTK6 (0.35) | P2RX3PTK6TTKMAPKAPK5FLT3 | |
| Hydrochloric Acid SCHEMBL30349841 | 0.92 | PTK6 (0.35) | P2RX3PTK6TTKMAPKAPK5FLT3 | |
| SCHEMBL25445314 | 0.91 | MAPKAPK5 (0.35) | P2RX3PTK6TTKMAPKAPK5CDK2 | |
| SCHEMBL24112476 | 0.91 | PTK6 (0.35) | P2RX3PTK6TTKMAPKAPK5CDK2 | |
| SCHEMBL22122891 | 0.90 | TTK (0.35) | P2RX3PTK6TTKMAPKAPK5CDK2 | |
| SCHEMBL22122968 | 0.90 | MAPKAPK5 (0.35) | P2RX3PTK6TTKMAPKAPK5CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | P2RX3 1517/4885PTK6 2141/4885TTK 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.